Biopharma
tkai long risk/reward 1.64Tkai massive upside potential. In other words, buy between .99 and current price 1.06 and aim to get out in the 1.2's. Current price is the high point of first wave up (the XA)..price descended appropriately (1--> .618) for support, and moved higher between the 1.21 and 1.41 exetension of XA. The following downtrend in price should suggest a move upwards to at LEAST 1.2s.
Fib numbers in a major downtrend?? GALEOne more retracement up followed by a downtrend would make fib numbers work for GALE price action. Food for thought
Why MSTX may not rise until at least 10/3With Section 8 Rules, I don't expect the shares to fall much lower than they already have. But, with Fib Time Trend, it looks like shares may not rise until at least Oct 3, maybe early next week? But with the possibility of being removed if shares fall to 6, I can't imagine them falling much more than another penny or so to around 9 before taking off. What say ye?
Sophiris (SPHS) Multi-month Ascending Broadening Wedge - BullishSPHS is in a multi-year ABW and with the latest partial decline, in addition to other important fundamental and technical factors, it will likely breakout upwards - To infinity and beyond!!
IBB BIOTECHRECENTLY most of the biotech companies are doing bad but somehow this ETF is going up. I saw weakness in technical analysis of monthly charts but weekly and daily needs to go down before shorting. Think this IBB bull will be ashort lived and once broken it will be a free fall zone. Leap options for short side will be a good bet. Don't go short yet but a good candidate for follow up.
Ligand Pharmaceuticals best choise in the Biopharma IndustryFundamentals :
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines worldwide. Ligand Pharmaceuticals has a compelling business model that offers higher than average return with lower than average risk.
Ligand's P/E of 8 is cheap as I mentioned. Forward P/E is indeed higher compared to the industry but I think it is still in range. Even if it is expensive, I think it is justified given the high return to equity that Ligand has generated in 2015. And as a growth stock, Ligand's growth comes at a cheaper price compared to the industry as represented by PE/G. So, do I think Ligand's a buy at this level? I think so
Technicals :
Price broke important level of resistance at $112 and had a nice run to $132. No we are in pullback, restesting previous resistance that now can act like support. And looks like we are curling up and can see new highs soon
Trade and Risk management:
We already have an initial entry, as price came out of consolidation above $121.40. I will initiate small position here with stop below $114.50 and will see if it can build new construction in front of high at $131.85 ot add to my position.
